Company Description: Cardinal Health Inc. is one of the leading wholesale distributors of pharmaceuticals, medical/surgical supplies and related products to a broad range of health care customers.
Fair Value: I consider four calculations of fair value, see page 2 of the linked PDF for a detailed description:
- Avg. High Yield Price
- 20-Year DCF Price
- Avg. P/E Price
- Graham Number
CAH is trading at a discount to 1.) and 3.) above. The stock is trading at a slight premium to its calculated fair value of $32.22. CAH did not earn any Stars in this section.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
- Free Cash Flow Payout
- Debt To Total Capital
- Key Metrics
- Dividend Growth Rate
- Years of Div. Growth
- Rolling 4-yr Div. > 15%
CAH earned three Stars in this section for 1.), 2.) and 3.) above. A Star was earned since the Free Cash Flow payout ratio was less than 60% and there were no negative Free Cash Flows over the last 10 years. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. CAH earned a Star for having an acceptable score in at least two of the four Key Metrics measured. Rolling 4-yr Div. > 15% means that dividends grew on average in excess of 15% for each consecutive 4 year period over the last 10 years (2000-2003, 2001-2004, 2002-2005, etc.) I consider this a key metric since dividends will double every 5 years if they grow by 15%. The company has paid a cash dividend to shareholders every year since 1983 and has increased its dividend payments for 14 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA)? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description:
- NPV MMA Diff.
- Years to > MMA
CAH earned a Star in this section for its NPV MMA Diff. of the $6,254. This amount is in excess of the $2,100 target I look for in a stock that has increased dividends as long as CAH has. If CAH grows its dividend at 17.6% per year, it will take 5 years to equal a MMA yielding an estimated 20-year average rate of 3.98%.
Other: CAH is a member of the S&P 500 and a member of the Broad Dividend Achievers™ Index.
Conclusion: CAH did not earn any Stars in the Fair Value section, earned three Stars in the Dividend Analytical Data section and earned one Star in the Dividend Income vs. MMA section for a total of four Stars. This quantitatively ranks CAH as a 4 Star-Buy.
Using my D4L-PreScreen.xls model, I determined the share price would need to increase to $48.44 before CAH’s NPV MMA Differential decreased to the $2,100 minimum that I look for in a stock with 14 years of consecutive dividend increases. At that price the stock would yield 1.44%.
Resetting the D4L-PreScreen.xls model and solving for the dividend growth rate needed to generate the target $2,100 NPV MMA Differential, the calculated rate is 14.1%. This dividend growth rate is less than the 17.6% used in this analysis, thus providing only a margin of safety. CAH has a risk rating of 1.50 which classifies it as a low risk stock.
CAH’s customer relationships and established distribution infrastructure provide notable scale advantages. Its diversified line of products and services provide good growth prospects for its contract drugmaking and its drug dispensing systems. The company is making steady progress in its performance initiatives by reducing the number of its generic drug suppliers, expanding its retail business and focusing on cost control. The stock is trading near my fair value price of $32.22. However, I am hesitate to buy with its yield at 2.19%. For additional information, including the stock’s dividend history, please refer to itsdata page.
No comments:
Post a Comment